Medicament for treatment of spleen-kidney yang deficiency syndrome type irritable bowel syndrome

Abstract

The invention provides a medicament for the treatment of spleen-kidney yang deficiency syndrome type irritable bowel syndrome, which comprises the following herbal materials: atragalus membranaceus, cdonopsis pilosula, stir-baked rhizoma dioscoreae, stir-baked white lablab bean, roasted rhizoma atractylodis macrocephalae, rhizoma atractylodis, pria cocos, rhizoma cimicifugae, radix puerariae, pericarpium citri reticulatae, magnolia officinalis, radix linderae, medicinal indianmulberry root, common fenugreek seed, desertliving cistanche, cassia bark, radix aconiti carmichaeli, radix glehniae, shisandra chinensis, semen euryales, herba portulacae, and radix glycyrrhizae preparata. Based on the TCM syndrome differentiation of the spleen-kidney yang deficiency syndrome type irritable bowel syndrome, in combination with the clinical manifestation of patients, and through the cmpatibility of prescription, the medicament achieves the effects of tonifying the spleen and the kidney, as well as regulating qi, inducing astringency and promoting salivation. Through treatment implemented by using the medicament, the medicament has a good therapeutic effect on the clinical symptoms and life quality of patients with spleen-kidney yang deficiency syndrome type irritable bowel syndrome; and the recurrence of the disease is significantly reduced, and then the occurrence of anxiety and depression is reduced.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicine, in particular to a medicine for treating irritable bowel syndrome of spleen-kidney yang deficiency syndrome. Background technique [0002] Irritable bowel syndrome (irritable bowel syndrome, IBS) is a functional bowel disease (functional bowel disease, FBD) characterized by abdominal pain or abdominal discomfort with changes in bowel habits. Limited to the colon, it is collectively referred to as irritable bowel syndrome. The disease lacks morphological changes and biochemical abnormalities that can explain the symptoms, and its incidence is increasing year by year, accounting for 25%-50% of digestive outpatient visits. According to the epidemiological survey, it is found that the disease is more common in women, with a male to female ratio of approximately 1:1 to 1:2, and the majority of the patients are middle-aged people aged 30 to 40. The prevalence of irritable bowel s...

AI Technical Summary

Problems solved by technology

[0009] The technical problem to be solved by the present invention is that the etiology and pathogenesis of this disease is not yet clear in Western medicine, and the treatment is mainly symptomatic treatment. For patients with persistent diarrhea, drugs such as antispasmodic and intestinal peristalsis are mainly selected, but often cause constipation in patients. , or diarrhea and constipation appear alternately, the patient’s quality of life declines, and the satisfaction with clinical efficacy is low.

Images